- UroToday Home
- Recent Abstracts
- Urologic Oncology
- Bladder Cancer
Conferences
ESMO 2024: What Is the Role of Rechallenge with the Same Class of Agents in Advanced Disease?
September 14, 2024
ESMO 2024: Novel Therapeutic Approaches for ARPI-resistant Disease
September 14, 2024
ESMO 2024: The Role of Urologist in Bladder Preservation Strategies
September 13, 2024
ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress
September 13, 2024
ESMO 2024: Clinical responders: Option of Chemoradiation?
September 13, 2024
ESMO 2024: Biomarkers and Prediction of Clinical Complete Response in Bladder Cancer
September 13, 2024
ESMO 2024: Will Theranostics Become Standard of Care?
September 13, 2024
ESMO 2024: Invited Discussant: Moving the Needle: Novel Targets and Refined Approaches in Genitourinary Cancers
September 13, 2024
ESMO 2024: NKT2152, a Novel Oral HIF-2α Inhibitor, in Participants with Previously Treated Advanced Clear Cell RCC: Preliminary Results of a Phase 1/2 Study
September 13, 2024
ESMO 2024: BL-B01D1-201: BL-B01D1, an EGFR x HER3 Bispecific Antibody-drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
September 13, 2024
ESMO 2024: Are Cytotoxics Still the Next Option?
September 13, 2024
ESMO 2024: Prospective Randomized Phase II Trial of Ipilimumab + Nivolumab Versus Standard of Care in Non-Clear Cell RCC: Results of the SUNNIFORECAST Trial
September 13, 2024
ESMO 2024: Final Analysis of the Phase 3 LITESPARK-005 Study of Belzutifan Versus Everolimus in Participants with Previously Treated Advanced Clear Cell RCC
September 13, 2024
Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024
September 11, 2024